# Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia

> **NCT06581081** · NA · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 130 (estimated)

## Conditions studied

- Relapsed Adult ALL
- B-cell Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Relapsed Pediatric ALL

## Interventions

- **BIOLOGICAL:** Senl_B19 autologous CAR-T (S1904) treatment

## Key facts

- **NCT ID:** NCT06581081
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581081, "Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06581081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*